Literature DB >> 22306407

Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris and mammalian cell expression.

Jonas V Schaefer1, Andreas Plückthun.   

Abstract

Aggregation is an important concern for therapeutic antibodies, since it can lead to reduced bioactivity and increase the risk of immunogenicity. In our analysis of immunoglobulin G (IgG) molecules of identical amino acid sequence but produced either in mammalian cells (HEK293) or in the yeast Pichia pastoris (PP), dramatic differences in their aggregation susceptibilities were encountered. The antibodies produced in Pichia were much more resistant to aggregation under many conditions, a phenomenon found to be mainly caused by two factors. First, the mannose-rich glycan of the IgG from Pichia, while slightly thermally destabilizing the IgG, strongly inhibited its aggregation susceptibility, compared to the complex mammalian glycan. Second, on the Pichia-produced IgGs, amino acids belonging to the α-factor pre-pro sequence were left at the N-termini of both chains. These additional residues proved to considerably increase the temperature of the onset of aggregation and reduced the aggregate formation after extended incubation at elevated temperatures. The attachment of these residues to IgGs produced in cell culture confirmed their beneficial effect on the aggregation resistance. Secretion of IgGs with native N-termini in the yeast system became possible after systematic engineering of the precursor proteins and the processing site. Taken together, the present results will be useful for the successful production of full-length IgGs in Pichia, give indications on how to engineer aggregation-resistant IgGs and shed new light on potential biophysical effects of tag sequences in general. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22306407     DOI: 10.1016/j.jmb.2012.01.027

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  19 in total

1.  General strategy for the generation of human antibody variable domains with increased aggregation resistance.

Authors:  Kip Dudgeon; Romain Rouet; Iris Kokmeijer; Peter Schofield; Jessica Stolp; David Langley; Daniela Stock; Daniel Christ
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

Review 2.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

3.  Advanced analyses of kinetic stabilities of iggs modified by mutations and glycosylation.

Authors:  Erik Sedlák; Jonas V Schaefer; Jozef Marek; Peter Gimeson; Andreas Plückthun
Journal:  Protein Sci       Date:  2015-06-11       Impact factor: 6.725

4.  Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.

Authors:  Paolo Arosio; Simonetta Rima; Massimo Morbidelli
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

5.  Aggregation and chemical modification of monoclonal antibodies under upstream processing conditions.

Authors:  Stefan Dengl; Marc Wehmer; Friederike Hesse; Florian Lipsmeier; Oliver Popp; Kurt Lang
Journal:  Pharm Res       Date:  2013-01-16       Impact factor: 4.200

6.  Modification of the kinetic stability of immunoglobulin G by solvent additives.

Authors:  Jonas V Schaefer; Erik Sedlák; Florian Kast; Michal Nemergut; Andreas Plückthun
Journal:  MAbs       Date:  2018-04-25       Impact factor: 5.857

Review 7.  Therapeutic protein aggregation: mechanisms, design, and control.

Authors:  Christopher J Roberts
Journal:  Trends Biotechnol       Date:  2014-06-04       Impact factor: 19.536

8.  A general approach to antibody thermostabilization.

Authors:  Audrey D McConnell; Xue Zhang; John L Macomber; Betty Chau; Joseph C Sheffer; Sorena Rahmanian; Eric Hare; Vladimir Spasojevic; Robert A Horlick; David J King; Peter M Bowers
Journal:  MAbs       Date:  2014       Impact factor: 5.857

9.  Increased Fab thermoresistance via VH-targeted directed evolution.

Authors:  Kevin C Entzminger; Jennifer L Johnson; Jeongmin Hyun; Raquel L Lieberman; Jennifer A Maynard
Journal:  Protein Eng Des Sel       Date:  2015-08-16       Impact factor: 1.650

Review 10.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.